Skip to search formSkip to main contentSkip to account menu

BMS-275183

Known as: BMS 275183, BMS275183 
An orally available, C-4 methyl carbonate analog of paclitaxel with potential antineoplastic activity. Like paclitaxel, BMS-275183 binds to tubulin… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Bridged-Ring Compounds
Microtubule Process

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies
SummaryPurpose BMS-275183 is an oral C-4 methyl carbonate analogue of paclitaxel that has the same mechanism of action… 
2009
2009
Metabolism and Excretion of an Oral Taxane Analog, [14C]3′-tert-Butyl-3′-N-tert-butyloxycarbonyl-4-deacetyl-3′-dephenyl-3′-N-debenzoyl-4-O-methoxy-paclitaxel (BMS-275183), in Rats and Dogs
3′-tert-Butyl-3′-N-tert-butyloxycarbonyl-4-deacetyl-3′-dephenyl-3′-N-debenzoyl-4-O-methoxy-paclitaxel (BMS-275183) is a taxane… 
2009
2009
CYP3A4-Mediated Ester Cleavage as the Major Metabolic Pathway of the Oral Taxane 3′-tert-Butyl-3′-N-tert-butyloxycarbonyl-4-deacetyl-3′-dephenyl-3′-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel (BMS…
3′-tert-Butyl-3′-N-tert-butyloxycarbonyl-4-deacetyl-3′-dephenyl-3′-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel (BMS-275183) is an… 
Review
2009
Review
2009
Epothilones: better or more of the same?
Agents that interfere with microtubule structure and function continue to play a major role in cancer treatment. The vinca… 
2009
2009
Metabolism and Excretion of an Oral Taxane Analog, [C]3 -tert- Butyl-3 -N-tert-butyloxycarbonyl-4-deacetyl-3 -dephenyl-3 -N- debenzoyl-4-O-methoxy-paclitaxel (BMS-275183), in Rats and Dogs
3 -tert-Butyl-3 -N-tert-butyloxycarbonyl-4-deacetyl-3 -dephenyl3 -N-debenzoyl-4-O-methoxy-paclitaxel (BMS-275183) is a taxane… 
2008
2008
Effect of Food on the Pharmacokinetic Behavior of the Potent Oral Taxane BMS-275183
Purpose: BMS-275183 is a potent oral paclitaxel analogue that previously showed promising activity. The goal of the present trial… 
2007
2007
BMS-275183-induced gene expression patterns in head and neck carcinoma.
2006
2006
644 POSTER The novel oral taxane BMS275183 has a favorable activity and toxicity profile in a twice weekly schedule; Preliminary findings from an extended phase I trial
2005
2005
A phase I trial investigating a twice weekly administration of the oral taxane BMS-275183 in patients with advanced solid tumors
2040 Background: BMS-275183, a novel oral taxane, had peripheral neuropathy as the main side effect on a weekly regimen with the… 
2005
2005
The effect of food on the pharmacokinetics of BMS-275183, a novel oral taxane, in patients with advanced solid malignancies
2053 Background: BMS-275183 is a novel oral taxane with promising activity against NSCLC and other tumor types. The effect of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)